Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer Institute

Drug Profile

Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer Institute

Alternative Names: anti-KRAS-mutation; anti-SSX2 TCR; KITE-439; KRAS TCR; NEO Antigens; SSX2 TCR

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Multiple myeloma

Most Recent Events

  • 22 Feb 2018 Kite Pharma and Sangamo Therapeutics enter into a collaboration for Zinc Finger Nuclease Technology
  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 08 Aug 2017 KITE plans a phase I trial of KITE 585 for Multiple myeloma (Second-line therapy or greater) in second half of 2017 (IV) (NCT03318861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top